Noninvasively silencing culprit genes in neurodegenerative disorders.
Ophidion, Inc. is an early-stage central nervous system (CNS) biopharmaceutical company leveraging its unique proprietary carrier technology to non-invasively deliver gene-silencing reagents and other large and small molecules directly to the brain across the blood-brain barrier (BBB). From this proprietary platform technology, OCCT, we have created a pipeline of disease-modifying and symptomatic therapeutics for serious and progressive neurodegenerative diseases.
Our current primary focus is the development and delivery of gene-silencing short interfering ribonucleic acids (siRNAs) and/or antisense oligonucleotides (ASOs) to the brain to treat Huntington’s disease and cognitive impairment, with future extension into other neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease. We expect to file an IND for our lead program in Huntington’s disease in 2022.
Contact us at [email protected].